Immix Biopharma, Inc.
For the period ended Dec 31, 2024. Filed Mar 25, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 25, 2025
IMMX$8.57+6.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
POWER OF ATTORNEY
Pursuant to the requirements of the Securities Act of 1934, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Ilya Rachman | Chief Executive Officer (Principal Executive Officer) and Chairman of the Board of Directors | March 24, 2025 |
| Ilya Rachman | ||
| /s/ Gabriel Morris | Chief Financial Officer and Director | March 24, 2025 |
| Gabriel Morris | (Principal Financial and Accounting Officer) | |
| /s/ Jason Hsu | Director | March 24, 2025 |
| Jason Hsu | ||
| /s/ Magda Marquet | Director | March 24, 2025 |
| Magda Marquet | ||
| /s/ Helen C. Adams | Director | March 24, 2025 |
| Helen C. Adams | ||
| /s/ Carey Ng | Director | March 24, 2025 |
| Carey Ng | ||
| /s/ Jane Buchan | Director | March 24, 2025 |
| Jane Buchan | ||
| /s/ Yekaterina Chudnovsky | Director | March 24, 2025 |
| Yekaterina Chudnovsky | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.